The patent application, with application number PCT/EP2019/068869, for which the EPO has issued an Intention to Grant notice, refers to the Thyrolytics’ biosensor product for use in detecting and quantifying the thyroid hormones T3 and T4 using a capillary blood sample. The patent protects the use of two key enzymes, DIO II and DIO III, for diagnostic applications. The notice of the Intention to Grant means that the EPO intends to approve the company’s patent application but that a number of administrative steps remain before a final notice of approval can be issued. The patent, when granted, provides protection of the device in Europe until 2039.
In addition to Europe, Aegirbio has submitted patent applications for Thyrolytics’s device in several other territories, including the United States, Japan India and China.
“The granting of a patent for our Thyrolytics device is an important part of our efforts to build value in our diagnostic patent portfolio. In addition to the device, Thyrolytics is developing an ambitious candidate drug aimed to aid 20% of hypothyroidism patients that do not respond to Levothyroxine today” says Mohamad Takwa, CEO of Thyrolytics.
“We are very pleased that the examination of our application was completed quickly and that we have now taken a big step towards obtaining a patent in a large and important market such the thyroidism market. In Sweden we have half a million thyroidism patients according to the Swedish thyroid association. With this we take an additional step towards becoming world leader in Therapeutic Drug Monitoring” says Martin Linde, CEO of Aegirbio.
Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.
The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment, while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs and suboptimal clinical outcomes.
The Company's tests for optimal dosing of biological drugs will be focused on neurological disorders, autoimmune diseases and cancer. In the first quarter of 2020, Aegirbio initiated sales in the U.S. of the MoNATor test for the drug Tysabri, which is used for treatment of the neurological disorder Multiple Sclerosis (MS). Aegirbio’s goal is to launch a total of four tests before 2023. Diagnostics will be offered through laboratory testing as well as in the form of a P.O.C. (Point of Care) test for use in hospitals and health centres. The plan further includes P.O.N. (Point of Need) tests for use at home.
For more information, please visit Aegirbio’s website, www.aegirbio.com
Certified adviser for the company is Eminova Fondkommission AB | +468-684 211 00 | firstname.lastname@example.org